Statins in the treatment of asthma

American Journal of Health-System Pharmacy

Volumn 70, Issue 19, 2013, Pages 1661-1669

  Walker, Derrica Y ^a   Edwards, Krystal L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; STEROID; ANTIASTHMATIC AGENT;

ANTIOXIDANT ACTIVITY; ASTHMA; CLINICAL TRIAL (TOPIC); COMORBIDITY; CORTICOSTEROID THERAPY; EMERGENCY WARD; FOLLOW UP; HOSPITALIZATION; HUMAN; INFLAMMATION; LUNG FUNCTION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; DRUG COMBINATION; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84899783230     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120680     Document Type: Review

References (47)

1. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma - summary report 2007. J Allergy Clin Immunol. 2007; 120(suppl 5):S94-138.
2. Lee YC, Lee KH, Lee HB et al. Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. J Asthma. 2001; 38:665-71.
3. Busse WW, Lemanske RF. Asthma. N Engl J Med. 2001; 344:350-62.
4. Humbert M, Ying S, Corrigan C et al. Bronchial mucosal expression of the genes encoding chemokines RANTES and MCP-3 in symptomatic atopic and nonatopic asthmatics: relationship to the eosinophil-active cytokines interleukin (IL)-5, granulocyte macrophage-colony-stimulating factor, and IL-3. Am J Respir Cell Mol Biol. 1997; 16:1-8.
5. Jeffery PK. Pathology of asthma. Br Med Bull. 1992; 48:23-39.
6. Bousquet J, Jeffery PK, Busse WW et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000; 161:1720-45.
7. Masoli M, Shirtcliffe P, Weatherall M et al. Inhaled corticosteroid therapy in the management of asthma in adults. In: Li JT, ed. Pharmacotherapy of asthma. New York: Taylor & Francis; 2006:83-115.
8. Bratt JM, Franzi LM, Linderholm AL et al. Arginase enzymes in isolated airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicol Appl Pharmacol. 2009; 234:273-80.
9. NO), lung function and airway hyperresponsiveness in naive atopic asthmatic children. J Asthma. 2004; 41:759-65.
10. Xu L, Dong XW, Shen LL et al. Simvastatin delivery via inhalation attenuates airway inflammation in a murine model of asthma. Int Immunopharmacol. 2012; 12:556-64.
11. Zeki AA, Franzi L, Last J et al. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med. 2009; 180:731-40.
12. Zeki AA, Bratt JM, Rabowsky M et al. Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling? Transl Res. 2010; 156:335-49.
13. Abdel Rahman MN, Abdelmotelb AA. Study of atorvastatin in experimental allergic airway inflammation in mice. Int Immunopharmacol. 2011; 11:1090-4.
14. Zhu T, Zhang W, Wang DX et al. Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor. Chin Med J. 2012; 125:1457-64.
15. Zeki AA, Thai P, Kenyon NJ et al. Differential effects of simvastatin on IL-13-induced cytokine gene expression in primary mouse tracheal epithelial cells. Respir Res. 2012; 13:38.
16. Menzies-Gow A, Ying S, Sabroe I et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol. 2002; 169: 2712-8.
17. Jinquan T, Quan S, Feili G et al. Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4. J Immunol. 1999; 162:4285-92.
18. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006; 8(suppl 2):S3.
19. Mckay A, Leung BP, Mcinnes IB et al. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol. 2004; 172:2903-8.
20. Kim DY, Ryu SY, Lim JE et al. Antiinflammatory mechanism of simvastatin in mouse allergic asthma model. Eur J Pharmacol. 2007; 557:76-86.
21. Ahmad T, Mabalirajan U, Sharma A et al. Simvastatin improves epithelial dysfunction and airway hyperresponsiveness: from asymmetric dimethyl-arginine to asthma. Am J Respir Cell Mol Biol. 2011; 44:531-9.
22. Chiba Y, Sato S, Misawa M. Upregulation of geranylgeranyltransferase I in bronchial smooth muscle of mouse experimental asthma: its inhibition by lovastatin. J Smooth Muscle Res. 2010; 46:57-64.
23. Ostroukhova M, Kouides RW, Friedman E. The effect of statin therapy on allergic patients with asthma. Ann Allergy Asthma Immunol. 2009; 103:463-8.
24. Menzies D, Nair A, Meldrum KT et al. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol. 2007; 119:328-35.
25. Moini A, Azimi G, Farivar A. Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial. Allergy Asthma Immunol Res. 2012; 4:290-4.
26. Hothersall EJ, Chaudhuri R, McSharry C et al. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax. 2008; 63:1070-5.
27. Cowan DC, Cowan JO, Palmay R et al. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax. 2010; 65:891-6.
28. Braganza G, Chaudhuri R, McSharry C et al. Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial. BMC Pulm Med. 2011; 11:16.
29. Keddissi JI, Younis WG, Chbeir EA et al. The use of statins and lung function in current and former smokers. Chest. 2007; 132:1764-71.
30. Alexeeff SE, Litonjua AA, Sparrow D et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med. 2007; 176:742-7.
31. Huang CC, Chan WL, Chen YC et al. Statin use in patients with asthma: a nationwide population-based study. Eur J Clin Invest. 2011; 41:507-12.
32. Lokhandwala T, West-Strum D, Banahan BF et al. Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis. BMJ Open. 2012; 2:e001279.
33. Juniper EF, Buist AS, Cox FM et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999; 115:1265-70.
34. Juniper EF, O'Byrne PM, Guyatt GH et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999; 14:902-7.
35. Juniper EF, Gruffydd-Jones K, Ward S et al. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J. 2010; 36:1410-6.
36. Schatz M, Sorkness CA, Li JT et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006; 117:549-56.
37. Almeida PC, Souza-Machado A, Leite Mdos S et al. Comparison between two methods of asthma control evaluation based on individual perception. J Bras Pneumol. 2012; 38:299-307.
38. Jia CE, Zhang HP, Lv Y et al. The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: systematic review and meta-analysis. J Allergy Clin Immunol. 2013; 131:695-703.
39. Khalili B, Boggs PB, Shi R et al. Discrepancy between clinical asthma control assessment tools and fractional exhaled nitric oxide. Ann Allergy Asthma Immunol. 2008; 101:124-9.
40. Huisa BN, Stemer AB, Zivin JA. Atorvastatin in stroke: a review of SPARCL and subgroup analysis. Vasc Health Risk Manag. 2010; 6:229-36.
41. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 highrisk individuals: a randomised placebocontrolled trial. Lancet. 2002; 360:7-22.
42. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 364:685-96.
43. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350:1495-1504.
44. Bartziokas K, Papaioannou AI, Minas M et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm Pharmacol Ther. 2011; 24:625-31.
45. Frost FJ, Petersen H, Tollestrup K et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007; 131:1006-12.
46. Søyseth V, Brekke PH, Smith P et al. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007; 29:279-83.
47. Johnson BA, Iacono AT, Zeevi A et al. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med. 2003; 167:1271-8.